Partillion Bioscience is a Los Angeles-based life science company developing a single-cell analysis platform. Its core product family centers on the proprietary Nanovial technology, a reagent-based platform that enables screening of individual cells based on difficult-to-probe functional information. Products are available through the company website and are designed to work with easy-to-access lab equipment, addressing a major industry pain point in functional single-cell assays. The company intends to use the new funding to accelerate growth and to launch new functional single-cell analysis and sorting product lines enabled by Nanovial technology. The underlying technology was developed in Dino Di Carlo’s lab at UCLA. The company is led by CEO Joe de Rutte.

Total raised

$5M

Funding rounds

1

Latest round

Seed

Latest activity

Sep 2023